title: Hypersplenism due to portal hypertension: retrospective evaluation of 17 patients treated by splenic embolization.
abstract: OBJECTIVE
  The objective of this retrospective study was to analyze the efficacy and morbidity associated with splenic artery embolization for hypersplenism due to portal hypertension (PHT), as a function of the volume of the splenic parenchyma embolized and the type of PHT (due to intrahepatic block or segmental PHT).
  
  
  METHODS
  This study retrospectively included 17 patients with hypersplenism secondary to PHT (intrahepatic block, n=14; segmental, n=3) treated by splenic artery embolization. The splenic volume embolized was estimated by computed tomography (CT) one month after embolization. A clinical assessment and platelet count took place at 7 days, 1 month and 6 months after the embolization.
  
  
  RESULTS
  In the group with PHT due to intrahepatic block, the mean volume of embolized splenic parenchyma was 63% of the initial volume (range: 30-95%). Six months later, the platelet level had increased by an average of 232%. All patients with fewer than 80,000 platelets/mL at 6 months had an embolization volume less than 50%. In the segmental PHT group, the mean volume of the embolized parenchyma was 62% of the initial volume (range: 20-95%), bleeding symptoms had disappeared in all patients, and the platelet level exceeded 80,000/mL. Six patients (6/17, 35%) had complications, two minor and four major: two splenic abscesses, one respiratory distress with ascites, and one pancreatitis with ascites. Five of the six complications were observed in patients with a volume of embolized splenic parenchyma more than 70%.
  
  
  CONCLUSIONS
  Our results show that splenic embolization of more than 50% of the parenchyma is effective in the treatment of hypersplenism due to PHT, but that when the embolized volume exceeds 70%, the procedure is associated with considerable morbidity.
authors.affiliation: Department of Radiology B, Gabriel Montpied Hospital, University Hospitals of Clermont-Ferrand, Clermont-Ferrand, France. antoine.petermann@free.fr
authors.forename: A
authors.initials: A
authors.lastname: Petermann
authors.forename: P
authors.initials: P
authors.lastname: Chabrot
authors.forename: L
authors.initials: L
authors.lastname: Cassagnes
authors.forename: E
authors.initials: E
authors.lastname: Dumousset
authors.forename: A
authors.initials: A
authors.lastname: Alfidja
authors.forename: C
authors.initials: C
authors.lastname: Gageanu
authors.forename: A
authors.initials: A
authors.lastname: Ravel
authors.forename: A
authors.initials: A
authors.lastname: Abergel
authors.forename: L
authors.initials: L
authors.lastname: Boyer
mesh_terms: D004621:Embolization, Therapeutic / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D006971:Hypersplenism / Q000000981:diagnostic imaging / Q000209:etiology* / Q000628:therapy*; D006975:Hypertension, Portal / Q000150:complications* / Q000000981:diagnostic imaging / Q000628:therapy*; D008875:Middle Aged; D015641:Radiography, Interventional; D012189:Retrospective Studies; D013157:Splenic Artery